Echinocandin pharmacodynamics: review and clinical implications
- PMID: 20335190
- DOI: 10.1093/jac/dkq081
Echinocandin pharmacodynamics: review and clinical implications
Abstract
Echinocandins have made a significant impact in the treatment of select invasive fungal infections, most notably invasive candidiasis and aspergillosis. However, treatment outcomes for such infections are still less than optimal, prompting an examination of dosing and administration techniques in an attempt to exploit known pharmacodynamic properties and improve outcomes. Echinocandins generally exhibit concentration-dependent, fungicidal activity against Candida spp. and fungistatic activity against Aspergillus spp. However, increasing drug concentrations of echinocandins above the organism's MIC may result in a paradoxical increase in fungal growth as demonstrated in some in vitro and in vivo models (known most commonly as the 'Eagle effect'). Therefore, the potential impact of dose escalations on improving the clinical efficacy of echinocandins based on in vitro and animal models are uncertain and are still being evaluated. In addition, such strategies have to consider the potential for increased treatment-related toxicities and costs. To date, published clinical studies (both superiority and non-inferiority) demonstrating the potential for dose-related improvements in treatment outcomes have been limited to mucocutaneous and oesophageal candidiasis. Further research is needed to determine if a role exists for optimizing echinocandin pharmacodynamics in various clinical settings.
Similar articles
-
Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies.Curr Opin Infect Dis. 2007 Dec;20(6):587-91. doi: 10.1097/QCO.0b013e3282f1bea3. Curr Opin Infect Dis. 2007. PMID: 17975408 Review.
-
Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections.J Antimicrob Chemother. 2009 Oct;64(4):840-4. doi: 10.1093/jac/dkp298. Epub 2009 Aug 21. J Antimicrob Chemother. 2009. PMID: 19700475
-
Echinocandins: the newest class of antifungals.Ann Pharmacother. 2009 Oct;43(10):1647-57. doi: 10.1345/aph.1M237. Epub 2009 Sep 1. Ann Pharmacother. 2009. PMID: 19724014 Review.
-
Pharmacodynamic implications for use of antifungal agents.Curr Opin Pharmacol. 2007 Oct;7(5):491-7. doi: 10.1016/j.coph.2007.05.004. Epub 2007 Jul 9. Curr Opin Pharmacol. 2007. PMID: 17616480 Review.
-
Update on echinocandin antifungals.Semin Respir Crit Care Med. 2008 Apr;29(2):211-9. doi: 10.1055/s-2008-1063859. Semin Respir Crit Care Med. 2008. PMID: 18366002 Review.
Cited by
-
The SAGA and NuA4 component Tra1 regulates Candida albicans drug resistance and pathogenesis.Genetics. 2021 Oct 2;219(2):iyab131. doi: 10.1093/genetics/iyab131. Genetics. 2021. PMID: 34849885 Free PMC article.
-
Antifungal resistance and new strategies to control fungal infections.Int J Microbiol. 2012;2012:713687. doi: 10.1155/2012/713687. Epub 2011 Dec 1. Int J Microbiol. 2012. PMID: 22187560 Free PMC article.
-
Novel method for evaluating in vitro activity of anidulafungin in combination with amphotericin B or azoles.J Clin Microbiol. 2012 Aug;50(8):2748-54. doi: 10.1128/JCM.00610-12. Epub 2012 Jun 12. J Clin Microbiol. 2012. PMID: 22692739 Free PMC article.
-
Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration.Clin Pharmacokinet. 2017 Sep;56(9):1057-1068. doi: 10.1007/s40262-016-0495-z. Clin Pharmacokinet. 2017. PMID: 28035589 Clinical Trial.
-
Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature.Eur J Med Res. 2011 Apr 28;16(4):167-79. doi: 10.1186/2047-783x-16-4-167. Eur J Med Res. 2011. PMID: 21486731 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous